After Emergency Use Authorization was granted for the messenger RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), persons at the highest risk for coronavirus disease 2019 (Covid-19)–related illness and death were prioritized for vaccination.1 Among these were pregnant women, yet they had been excluded from initial vaccine trials. Pregnant women and their clinicians were left to weigh the documented risks of Covid-19 infection against the unknown safety risks of vaccination in deciding whether to receive the vaccine. Before the vaccine rollout, multiple cohort studies documented that pregnant women were at greater risk than nonpregnant women for severe disease after Covid-19https://www.nejm.org/doi/full/10.1056/NEJMe2107070?rss=mostViewed
The views and opinions expressed in this feed are those of the authors and do not necessarily reflect the official policy or position of Elizabeth Pharmacy. Elizabeth Pharmacy does not warrant the accuracy, timeliness or completeness of the information contained on this feed. If you have a particular complaint about something you’ve found on this web site, feel free to contact us.